ProCE Banner Activity

CE / CME

An Update on Optimizing Care for Myelodysplastic Syndromes

Text Module

Get insights from Amer Zeidan, MBBS, MPH on some of the most important developments in optimizing the management of myelodysplastic syndromes, including results from a patient survey, clinical trial findings, and implications for clinical practice.

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: November 22, 2023

Expiration: November 21, 2024

Share

Faculty

Amer Zeidan

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Provided by

Provided by Clinical Care Options LLC, in partnership with The Myelodysplastic Syndromes Foundation, Inc

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Geron, and Karyopharm Therapeutics.

AbbVie Inc.

Geron

Karyopharm Therapeutics

Partners

MDS Foundation

ProCE Banner

Target Audience

This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals who care for patients with MDS. This educational program is also intended to reach patients with MDS and their caregivers.

Program Learning Goal

The goal of this activity is to educate oncologists, oncology nurses, pharmacists, other healthcare professionals, and patients about recent developments in the treatment of myelodysplastic neoplasms to optimally individualize therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized therapeutic strategies for patients with MDS based on the new WHO and ICC guidelines, patient and disease characteristics, and validated risk stratification tools

  • Employ the latest data on dosing frequency and escalation and durability of response when considering treatment of patients with very low–risk, low-risk, or intermediate-risk MDS

  • Develop care plans that recognize and identify early ESA treatment failure in patients with MDS

  • Evaluate the available clinical data on first-in-class therapeutic approaches, promising investigational agents, and emerging combination therapies for managing high-risk MDS

  • Implement evidence-based management of adverse events associated with current and recently approved systemic therapies in MDS

  • Contribute to informed, equitable care discussions and planning through shared decision-making, education, and resources

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Amer Zeidan, MBBS, MPH: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Celgene, Geron, Incyte, Medimmune, Novartis, Otsuka, Pfizer, Shattuck Labs, Takeda, Trovagene; consultant: AbbVie, Acceleron, Agios, ALX Oncology, Amgen, Aprea, Astellas, BeyondSpring, Biocryst, Bristol Myers Squibb, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Foran, Genentech, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Seattle Genetics, Servier, Syndax, Syros, Taiho, Takeda, Trovagene, Tyme.

The planners and content peer reviewers from Clinical Care Options, LLC and the Myelodysplastic Syndromes Foundation, Inc do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 22, 2023, through November 21, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material  for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education


CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-304-H01-P
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to NABP CPE Monitor Services within 60 days.